Cost-Effectiveness Analysis of Trastuzumab in the Adjuvant Treatment for Early Breast Cancer

CC4 COST-EFFECTIVENESS ANALYSIS OF PERTUZUMAB WITH TRASTUZUMAB AND CHEMOTHERAPY COMPARED TO TRASTUZUMAB AND CHEMOTHERAPY IN THE ADJUVANT TREATMENT FOR PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE IN CHINA

Value in Health ◽

10.1016/j.jval.2019.09.048 ◽

2019 ◽

Vol 22 ◽

pp. S405-S406

Author(s):

X. Guan ◽

H. Li ◽

Q. Chen ◽

C. Hao ◽

J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

High Risk ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Her2 Positive ◽

Risk Of Recurrence ◽

Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States

American Journal of Clinical Oncology ◽

10.1097/coc.0000000000000816 ◽

2021 ◽

Vol Publish Ahead of Print ◽

Author(s):

Jesse Sussell ◽

Gurleen Singh Jhuti ◽

Vincent Antao ◽

Oscar Herrera-Restrepo ◽

Elizabeth Wehler ◽

...

Keyword(s):

Breast Cancer ◽

United States ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

The United States ◽

Trastuzumab Emtansine ◽

PCN31 Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment for Patients with HER2-Positive EARLY Breast Cancer: Update Results after National Drug Reimbursement LIST Adjustment in China

Value in Health Regional Issues ◽

10.1016/j.vhri.2020.07.081 ◽

2020 ◽

Vol 22 ◽

pp. S10

Author(s):

X. Guan ◽

H.C. Li ◽

Q.J. Chen ◽

C.F. Hao ◽

J.J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Her2 Positive ◽

Drug Reimbursement ◽

Effectiveness Analysis ◽

National Drug ◽

Reimbursement List

PCN103 Cost-Effectiveness Analysis of Trastuzumab Emtansine for Adjuvant Treatment of Adult Patients with HER2+ EARLY Breast Cancer in Turkey

Value in Health ◽

10.1016/j.jval.2020.08.240 ◽

2020 ◽

Vol 23 ◽

pp. S441

Author(s):

B. Akyol Ersoy ◽

E. Erdogan-Ciftci ◽

L. Yanik ◽

B. Guler ◽

G. Ozcan

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Adult Patients ◽

Trastuzumab Emtansine ◽

58P Cost-effectiveness analysis of trastuzumab emtansine versus trastuzumab for Chinese patients with residual invasive HER2-positive early breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.03.072 ◽

2021 ◽

Vol 32 ◽

pp. S45

Author(s):

X. Guan ◽

H-C. Li ◽

Q-J. Chen ◽

B. Hua ◽

J-J. Li ◽

...

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Chinese Patients ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1909478 ◽

2021 ◽

pp. 1-10

Author(s):

Carlos Henrique Botelho ◽

Maria Del Pilar Estevez-Diz ◽

Alessandro Gonçalves Campolina

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Abstract A30: Cost‐effectiveness analysis of HER2 testing methods in adjuvant treatment of HER2 breast cancer

10.1158/1940-6207.prev-09-a30 ◽

2010 ◽

Author(s):

Mahima Ashok ◽

Paul Griffin ◽

Michael Halpern

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Treatment ◽

Testing Methods ◽

Her2 Testing ◽

Her2 Breast Cancer ◽

Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China

Clinical Drug Investigation ◽

10.1007/s40261-019-00842-0 ◽

2019 ◽

Vol 40 (1) ◽

pp. 25-32 ◽

Cited By ~ 2

Author(s):

Xiaoxia Wei ◽

Hong Sun ◽

Jie Zhuang ◽

Xiuhua Weng ◽

Bin Zheng ◽

...

Keyword(s):

Breast Cancer ◽

Estrogen Receptor ◽

Cost Effectiveness ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Early Breast Cancer ◽

Pharmacogenetic Testing ◽

Effectiveness Analysis ◽

Estrogen Receptor Positive

Multi-arm Cost-Effectiveness Analysis (CEA) comparing different durations of adjuvant trastuzumab in early breast cancer, from the English NHS payer perspective

PLoS ONE ◽

10.1371/journal.pone.0172731 ◽

2017 ◽

Vol 12 (3) ◽

pp. e0172731 ◽

Cited By ~ 6

Author(s):

Caroline S. Clarke ◽

Rachael M. Hunter ◽

Ian Shemilt ◽

Victoria Serra-Sastre

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Early Breast Cancer ◽

Adjuvant Trastuzumab ◽

Effectiveness Analysis ◽

Payer Perspective

PCN11 COST-EFFECTIVENESS ANALYSIS OF DOSE-DENSE CHEMOTHERAPY WITH FILGRASTIM AS POSTOPERATIVE ADJUVANT TREATMENT OF BREAST CANCER

Value in Health ◽

10.1016/s1098-3015(10)62153-5 ◽

2004 ◽

Vol 7 (3) ◽

pp. 249

Author(s):

Yu AP ◽

JW Hay

Keyword(s):

Breast Cancer ◽

Cost Effectiveness ◽

Adjuvant Treatment ◽

Effectiveness Analysis ◽

Dose Dense ◽

Postoperative Adjuvant Treatment